Locally Advanced or Metastatic Urothelial CancerUrothelial Cancer
Study summary
The ARON-2PLUS Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of Enfortumab vedotin plus Pembrolizumab as first-line therapy in patients with locally advanced/metastatic Urothelial Cancer.
Two supplementary optional studies are designed: one is related to CT scans evaluation for 3D reconstruction analysis; the other one is an omic analysis on FFPE tissue.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients aged \>18years
* Histologically confirmed diagnosis of la/mUC of upper and/or lower urinary tract or histologically confirmed diagnosis of rare GU tumors.
* Histologically or radiologically confirmed metastatic disease
* Patients treated with first-line EV+P combination
Exclusion Criteria:
* Patients without histologically confirmed diagnosis of UC
* Patients without histologically or radiologically confirmed la or mUC
Primary outcome measure(s)
overall survival in patients with la/mUC or rare GU tumors — December 2030 time from the start of the therapy until death from any cause
progression-free survival — December 2030 time from the start of the therapy until progression or death from any cause.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
